SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes undergoing emergency surgery was not associated with ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...